



Subpopulation Analysis in Causal Inference: A Healthcare Case Study

Georgios Mavroudeas, Nafis Neehal,
Jason Kuruzovich, Kristin P. Bennett,
Malik Magdon-Ismail

Rensselaer Polytechnic Institute,
Troy, NY, USA.

Background

- RCTs - gold standard for treatment evaluation
- Problem arises in presence of heterogeneous treatment effects (HTE)
 - ATT becomes a combination of multiple effect levels
 - Biased treatment effect estimation

Our Contribution

- Machine Learning based Causal Estimation Procedure
 - Applicable for contexts in which HTE is present in complex subpopulations
- End-to-end framework based on matching and unsupervised learning
 - Non-parametric approach



Problem Setup

- A subject is a tuple $s = (x, c, t, y)$
 - Sampled from distribution D
 - x is the d -dimensional feature vector
 - c is the effect-level subpopulation to which the subject belongs
 - t is binary treatment assignment
 - Y is the observed outcome
- S^T and S^C are all treated and control population with N^T and N^C number of subjects
- We want to identify -
 - If there exist meaningful subpopulations with heterogeneous treatment effects within a population
 - How this heterogeneity affects the population-level estimation of ATE

Methodology




Fig. 1: Overview of workflow. (a) Stage 1: Matching to get counterfactuals. (b) Stage 2: **PCM** to recover effect-subpopulations.

Goals

- Let S^T and S^C be treated and untreated controls respectively
- Goal 1:
 - for each subject S^T estimate the counterfactual \tilde{v}
- Goal 2:
 - uncover the hidden effect levels C_1, \dots, C_L where L denotes the number of hidden effect levels
 - Assign each treated subject $s \in S^T$ to its corresponding effect-level group c

Stage 1: Counterfactual Estimation

- We use a hybrid matching technique described in [9]
 - To produce counterfactual outcomes (\tilde{v}) for each treated subject (S^T)
- Combines
 - K-nearest neighbors
 - Exact matching
 - Coarsened exact matching
- Reason:
 - some features in the health space should be exactly controlled for, like age and ER-visits, while others can be approximately matched, like blood pressure and weight.

Stage 2: Determine Effect-Levels

- Each treated $s \in S^T$ is now a tuple $s = (x, v, \tilde{v})$
 - x is the feature, v is the observed outcome, \tilde{v} is the estimated counterfactual outcome
- Determine subpopulation effect-levels L
- Assign each treated subject $s \in S^T$ to a level c_i using a pre-cluster and merge (PCM) algorithm developed in [3]
 - Cluster using features x
 - Compute treatment effects within each cluster
 - Group clusters into effect levels using PCM
 - Assign subjects to subpopulations and estimate subpopulation effects

Case Study

- Effectiveness of health intervention (HI) program for pre-diabetics
 - Proprietary data from a local health insurance provider
 - 1604 patients enrolled between November 2017 and April 2021 – treated group
 - 350k patients in the control group
 - Features included demographics, lab results, prior health conditions, and history of events (Acute Care, Inpatient Care, and Emergency Visits) within the last 2 and 6 months
- The goal was to evaluate this program
 - Measured by survival analysis on the time it takes after enrollment in HI for a patient to use acute care (in-patient or ER usage)

Results and Discussion (Whole Treated Population)

- Compare Restricted Mean Survival Time (RMST) from Kaplan Meier Curves
 - Between treated and matched controls
- Dotted vertical line is the start of the intervention
- Significant positive treatment effect with p-value 0.01
- Matching process produces near identical survival curves prior to HI, as it should




Fig: Kaplan Meier curves, on the outcome: "Time to Acute Care" for all treated population.

Results and Discussion (ATE Clusters)

- PCM Algorithm with agglomerative clustering and 10 clusters
- Visual inspection suggests three effect levels of $[0, 0.2]$, $[0.3, 0.4]$, and 0.85
- Competing techniques for learning HTE based on decision trees were not able to recover this
- Merging clusters results in three final effect-levels
 - Sick (with zero effect)
 - Healthy (with positive effect)
 - Critical (with very positive effect)




Fig: Clusters of ATE (18 Month RMST) retrieved by PCM

Results and Discussion (Effect-Level Subgroup Analysis)




Fig. 2: Kaplan Meier's, survival curves for "Time to Acute Care." (a) "Sick" subpopulation with no effect ($p = 0.44$). (b) "Healthy" subpopulation with positive effect ($p = 0.01$). (c) "Critical" subpopulation with large positive effect ($p = 0.08$).

Results and Discussion (Effect-Level Subgroup Analysis)

TABLE I: Feature breakdown of the subpopulations from **PCM**. The p-value quantifies how well matched the subpopulation is w.r.t. its controls, with respect to a given feature (high p-value means the controls match the subpopulation). The “*” means that in both treated and matched controls the feature was always 0.

| | Subpopulations found by PCM | | | |
|---------------------------|-------------------------------|------------------------------|---------------------------------|----------------------------------|
| | <i>Treated Population</i> | <i>Sick, No Effect</i> | <i>Healthy, Positive Effect</i> | <i>Critical, Positive Effect</i> |
| | <i>mean (p-value), N=1364</i> | <i>mean (p-value), N=767</i> | <i>mean (p-value), N=516</i> | <i>mean (p-value), N=81</i> |
| <i>Age</i> | 50.77 (0.86) | 51.52 (0.88) | 50.08 (0.92) | 48.06 (0.99) |
| <i>Total Cost</i> | 705.78 (0.34) | 798.16 (0.66) | 462.72 (0.56) | 1379.32 (0.19) |
| <i>Gender</i> | 0.21(1.0) | 0.35 (1.0) | 0.02 (1.0) | 0.16 (1.0) |
| <i>Tobacco Use</i> | 0.06 (0.37) | 0.0 (0.0) | 0.0 (0.08) | 1.0 (0.0) |
| <i>Pressure</i> | 0.0 (0.4) | 0.0 (0.4) | 0.0 (*) | 0.0 (*) |
| <i>Obesity</i> | 0.5 (0.51) | 0.74 (0.18) | 0.13 (0.41) | 0.6 (0.68) |
| <i>Hypertension</i> | 0.34 (0.36) | 0.38 (0.65) | 0.26 (0.51) | 0.46 (0.44) |
| <i>Hypothyroid</i> | 0.1 (0.05) | 0.18 (0.02) | 0.0 (0.12) | 0.04 (0.91) |
| <i>Disease Count</i> | 2.9 (0.66) | 3.48 (0.66) | 1.74 (0.95) | 4.79 (0.55) |
| <i>Acute Care 2</i> | 0.04 (0.35) | 0.04 (0.32) | 0.02 (0.95) | 0.12 (0.77) |
| <i>Acute Care 6</i> | 0.11 (0.97) | 0.12 (0.95) | 0.06 (0.96) | 0.3 (0.97) |
| <i>Inpatient Care 6</i> | 0.02 (1.0) | 0.03 (1.0) | 0.0 (1.0) | 0.07 (1.0) |
| <i>Emergency Visits 6</i> | 0.09 (0.91) | 0.09 (0.91) | 0.06 (1.0) | 0.23 (0.94) |
| <i>Line of Bussiness</i> | 0.96 (1.0) | 0.95 (1.0) | 0.99 (1.0) | 0.84 (1.0) |

Conclusion

- Our work extends the causal analysis to non-targeted health interventions and clinical trials -
 - treated population can consist of subpopulations exhibiting different effects to the treatment
- Novel PCM strategy finds three subpopulations with significantly different effects
- Strength of PCM was showcased on an appropriate case study
- Essential if one is to best understand the benefits and side-effects of a treatment